An oral selective M3 cholinergic receptor antagonist in COPD

European Respiratory Journal

Volumn 28, Issue 4, 2006, Pages 772-780

  Lu, S ^a   Parekh, D D ^a   Kuznetsova, O ^a   Green, S A ^a   Tozzi, C A ^a   Reiss, Theodore F ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Anticholinergics; Antimuscarinic agents; Bronchodilators; Chronic obstructive pulmonary disease; Ipratropium bromide; Muscarinic receptors

Indexed keywords

BECLOMETASONE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; FLUTICASONE; IPRATROPIUM BROMIDE; MUSCARINIC M3 RECEPTOR; MUSCARINIC M3 RECEPTOR ANTAGONIST; PLACEBO; PREDNISONE; THEOPHYLLINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; MUSCARINIC RECEPTOR BLOCKING AGENT;

ABNORMAL LABORATORY RESULT; ADULT; AGED; ANAMNESIS; ARTICLE; BRONCHODILATATION; CARDIOVASCULAR DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG SELECTIVITY; DRUG TOLERABILITY; DRY THROAT; EYE DISEASE; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; MAJOR CLINICAL STUDY; MALE; MICTURITION DISORDER; MULTICENTER STUDY; OLIGURIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TACHYCARDIA; TREATMENT OUTCOME; TREATMENT RESPONSE; UNITED STATES; URINE RETENTION; VISUAL ACUITY; VISUAL DISORDER; XEROSTOMIA; DRUG ANTAGONISM; LUNG FUNCTION TEST; MIDDLE AGED;

ADULT; AGED; AGED, 80 AND OVER; CHOLINERGIC ANTAGONISTS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IPRATROPIUM; MALE; MIDDLE AGED; MUSCARINIC ANTAGONISTS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RECEPTOR, MUSCARINIC M3; RESPIRATORY FUNCTION TESTS;

EID: 33751191290     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.06.00126005     Document Type: Article

References (21)

1. National Heart, Lung, and Blood Institute. Morbidity & Mortality: 2004 chart book on cardiovascular, lung and blood diseases. U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health, Bethesda MD. http://www.nhlbi.nih.gov/resources/ docs/04-chtbk.pdf. Date last updated: May 2004. Date last accessed: September 2005.
2. Mannino DM, Homa DM, Akimbani LJ, Ford ES, Redd SC. Chronic obstructive pulmonary disease surveillance-United States, 1971-2000. MMWR Surveill Summ 2002; 51: 1-16.
3. Lopez AD, Murray CC. The global burden of disease 1990-2020. Nat Med 1998; 4: 1241-1243.
4. Anthonisen NR, Connett JE, Kiley JP, et al. Effect of smoking intervention and the use of an inhaled anti-cholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. JAMA 1994; 272: 1497-1505.
5. Wagena EJ, van der Meer RM, Ostelo RJ, Jacobs JE, van Schayck CP. The efficacy of smoking cessation strategies in people with chronic obstructive pulmonary disease: results from a systemic review. Respir Med 2004; 98: 805-815.
6. Highland KB. Inhaled corticosteroids in chronic obstructive pulmonary disease: is there a long-term benefit? Curr Opin Pulm Med 2004; 10: 113-119.
7. Angeli P. Pentatomic cyclic agonists and muscarinic receptors: a 20 years review. Farmaco 1995; 50: 565-577.
8. Barnes PJ. Muscarinic receptor subtypes: implications for therapy. Agents Actions Suppl 1993; 43: 243-252.
9. Mitsuya M, Mase T, Tsuchiya Y, et al. J-10429, a novel muscarinic M3 receptor antagonist with high selectivity for M3 over M2 receptors. Bioorg Med Chem 1999; 7: 2555-2567.
10. Beeh KM, Welte T, Buhl R. Anticholinergics in the treatment of chronic obstructive pulmonary disease. Respiration 2002; 69: 372-379.
11. Gross NJ. Anticholinergic agents in asthma and COPD. Eur J Pharmacol 2006; 533: 36-39.
12. Bestall JC, Paul EA, Garrod R, Gamham R, Jones PW, Wedzicha JA. Usefulness of the Medical Research Council (MRC) dyspnea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax 1999; 54: 581-586.
13. Crapo RO, Morris AH, Gardner RM. Reference spirometric values using techniques and equipment that meet ATS recommendations. Am Rev Respir Dis 1981; 123: 659-664.
14. Malmstrom K, Peszek I, Botto A, Lu S, Enright PL, Reiss TF. Quality assurance of asthma clinical trials. Control Clin Trials 2002; 23: 143-156.
15. Witek TJ, Mahler DA. Meaningful effect size and patterns of response of the transition dyspnea index. J Clin Epidemiol 2003; 56: 248-255.
16. Guyatt GH, Berman LB, Townsend M, Pugsley SO, Chambers LW. A measure of quality of life for clinical trials in chronic lung disease. Thorax 1987; 42: 773-778.
17. Reiss TF, Chervinsky P, Dockhorn RJ, Shingo S, Seidenberg B, Edwards TB. Montelukast, once-daily leukotriene receptor antagonist, in the treatment of chronic asthma. Arch Intern Med 1998; 158: 1213-1220.
18. Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS, GOLD Scientific Committee, Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO global initiative for chronic obstructive lung disease (GOLD) workshop summary. Am J Respir Crit Care Med 2001; 163: 1256-1276.
19. Volovitz B, Duenas-Meza E, Chmielewska-Szewczyk DA, et al. Comparison of oral montelukast and inhaled cromolyn with respect to preference, satisfaction, and adherence: a multicenter, randomized, open-label, cross-over study in children with mild to moderate persistent asthma. Curr Ther Res 2000; 61: 490-506.
20. van Noord JA, Bantje TA, Eland ME, Korducki L, Cornelissen PJ. A randomized controlled comparison of tiotropium and ipratropium in the treatment of chronic obstructive pulmonary disease. Thorax 2000; 55: 289-294.
21. Haab F, Stewart L, Dwyer P. Darifenacin, an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder. Eur Urol 2004; 45: 420-429.